Baseline characteristics of the study population according to median HbA1c at 13 weeks
| Variable | Week 13 HbA1c <7.7% | Week 13 HbA1c ≥7.7 | ||||
| All n=2036 | Placebo n=912 | Canagliflozin n=1124 | All n=2162 | Placebo n=1187 | Canagliflozin n=975 | |
| Demographics | ||||||
| Age (years) | 63.4 (9.5) | 63.6 (9.4) | 63.2 (9.6) | 62.4 (8.8) | 62.7 (9.0) | 62.1 (8.6) |
| Female | 588 (28.9) | 264 (28.9) | 324 (28.8) | 830 (38.4) | 429 (36.1) | 401 (41.1) |
| Race | ||||||
| White | 1332 (65.4) | 577 (63.3) | 755 (67.2) | 1469 (67.9) | 803 (67.6) | 666 (68.3) |
| Black | 95 (4.7) | 44 (4.8) | 51 (4.5) | 116 (5.4) | 61 (5.1) | 55 (5.6) |
| Asian | 437 (21.5) | 212 (23.2) | 225 (20.0) | 400 (18.5) | 222 (18.7) | 178 (18.3) |
| Other or unknown | 172 (8.4) | 79 (8.7) | 93 (8.3) | 177 (8.2) | 101 (8.5) | 76 (7.8) |
| Comorbidities | ||||||
| Hypertension | 1967 (96.6) | 879 (96.4) | 1088 (96.8) | 2097 (97.0) | 1154 (97.2) | 943 (96.7) |
| Heart failure | 289 (14.2) | 131 (14.4) | 158 (14.1) | 336 (15.5) | 183 (15.4) | 153 (15.7) |
| Cardiovascular disease | 328 (16.1) | 171 (18.8) | 157 (14.0) | 345 (16.0) | 176 (14.8) | 169 (17.3) |
| Duration of diabetes (years) | 15.2 (8.7) | 15.8 (8.9) | 14.7 (8.6) | 16.3 (8.4) | 16.2 (8.2) | 16.5 (8.6) |
| Blood pressure and labs | ||||||
| Systolic BP (mm Hg) | 139.8 (15.6) | 140.0 (15.6) | 139.6 (15.7) | 140.4 (15.6) | 140.7 (15.6) | 140.0 (15.6) |
| Diastolic BP (mm Hg) | 78.1 (9.4) | 77.7 (9.4) | 78.4 (9.3) | 78.6 (9.3) | 79.0 (9.3) | 78.1 (9.4) |
| HbA1c (%) | 7.5 (0.9) | 7.4 (0.9) | 7.5 (0.9) | 9.0 (1.2) | 8.9 (1.3) | 9.1 (1.2) |
| eGFR (mL/min/1.73 m2) | 55.5 (16.2) | 55.5 (16.3) | 55.6 (16.2) | 57.1 (16.6) | 57.0 (16.7) | 57.2 (16.4) |
| UACR (mg/g) | 1385 (1118) | 1425 (1157) | 1354 (1084) | 1454 (1143) | 1423 (1106) | 1492 (1186) |
BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; UACR, urinary albumin to creatinine ratio.